Perspectives for cancer prevention with natural compounds

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2712-2725

  Amin, A R M Ruhul ^a   Kucuk, Omer ^a   Khuri, Fadlo R ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALPHA TOCOPHEROL DERIVATIVE; ARSENIC TRIOXIDE; CELECOXIB; CISPLATIN; CURCUMIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ELLAGIC ACID; ERLOTINIB; FATTY ACID; GEMCITABINE; GENISTEIN; GREEN TEA EXTRACT; ISOFLAVONE; LUTEOLIN; LYCOPENE; N 3 POLY UNSATURATED FATTY ACID; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLANT MEDICINAL PRODUCT; POMEGRANATE EXTRACT; RESVERATROL; RETINOIC ACID; SULINDAC; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ACUTE MYELOBLASTIC LEUKEMIA; ADENOMATOUS POLYP; ANTIOXIDANT ACTIVITY; BEVERAGE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLITIS; COLON CANCER; COLORECTAL CANCER; DIET; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FAMILIAL ADENOMATOUS POLYPOSIS; FOLLICULAR LYMPHOMA; FOOD INTAKE; FRUIT; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LEUKOPLAKIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAINTENANCE THERAPY; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; POMEGRANATE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECTUM CANCER; REVIEW; SKIN CANCER; SOFT TISSUE CALCIFICATION; SOFT TISSUE CANCER; SOLID TUMOR; TEA; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; VEGETABLE; ANIMAL; BODY WEIGHT; CHEMISTRY; DRUG EFFECT; EXERCISE; ISOLATION AND PURIFICATION; METABOLISM; MORTALITY; NEOPLASM; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL PRODUCTS; BODY WEIGHT; DIET; DIETARY SUPPLEMENTS; EXERCISE; FRUIT; HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SIGNAL TRANSDUCTION; VEGETABLES;

EID: 66849095259     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6235     Document Type: Review

References (189)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 58:71-96, 2008
2. Strong K, Mathers C, Epping-Jordan J, et al: Preventing cancer through tobacco and infection control: How many lives can we save in the next 10 years? Eur J Cancer Prev 17:153-161, 2008
3. Glade MJ: Food, nutrition, and the prevention of cancer: A global perspective: American Institute for Cancer Res/World Cancer Res Fund, American Institute for Cancer Res, 1997. Nutrition 15:523-526, 1999
4. Haddad RI, Shin DM: Recent development in head and neck cancer. N Engl J Med 359:1143-1154, 2008
5. Berenblum I: The modifying influence of dichloroethyl sulphide on the induction of tumours in mice by tar. J Pathol Bacteriol 32:425-434, 1929
6. Sporn MB, Dunlop NM, Newton DL: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338, 1976
7. Hong WK, Endicott J, Itri LM, et al: 13-cisretinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
8. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
9. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:825-827, 1990
10. Benner SE, Pajak TF, Lippman SM, et al: Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck. J Natl Cancer Inst 86:140-141, 1994
11. Pastorino U, Chiesa E, Infante M, et al: Safety of high dose vitamin A. Randomized trial on lung cancer chemoprevention. Oncology 48:131-137, 1991
12. Lippman SM, Lee JJ, Karp DD, et al: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-smallcell lung cancer. J Natl Cancer Inst 93:605-618, 2001
13. Khuri FR, Lee JJ, Lippman SM, et al: Randomized phase III trial of low dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98:426-427, 2006
14. Shin DM, Khuri FR, Murphy B, et al: Combined interferon-alfa, 13-cis-retinoic acid and alfatocoferol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant phase II trial. J Clin Oncol 19:3010-3017, 2001
15. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006
16. Khuri FR, Cohen V: Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 10:4249s-4253s, 2004
17. Zhang Z, Wang Y, Lantry LE, et al: Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene 22:6257-6265, 2003
18. Choe MS, Zhang X, Shin HJC, et al: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4:1448-1455, 2005
19. Reddy L, Odhav B, Bhoola KD: Natural products for cancer prevention: A global perspective. Pharmacol Ther 99:1-13, 2003
20. Block G, Patterson B, Suber A: Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr Cancer 18:1-29, 1992
21. Benetou V, Orfanos P, Lagiou P, et al: Vegetables and fruits in relation to cancer risk: Evidence from the Greek EPIC cohort study. Cancer Epidemiol Biomarkers Prev 17:387-392, 2008
22. Freedman ND, Park Y, Subar AF, et al: Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. Int J Cancer 122:2330-2336, 2008
23. Steinmetz KA, Potter JD: Vegetables, fruit, and cancer prevention: A review. J Am Diet Assoc 96:1027-1039, 1996
24. Imai K, Suga K, Nakachi K: Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26:769-775, 1997
25. Nakachi K, Suemasu K, Suga K, et al: Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89:254-261, 1998
26. Jian L, Xie LP, Lee AH, et al: Protective effect of green tea against prostate cancer: A casecontrol study in southeast China. Int J Cancer 108: 130-135, 2004
27. Wu AH, Yu MC, Tseng CC, et al: Green tea and risk of breast cancer in Asian Americans. Int J Cancer 106:574-579, 2003
28. Khan N, Afaq F, Mukhtar H: Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal 10:475-510, 2008
29. Bushman JL: Green tea and cancer in humans: A review of the literature. Nutr Cancer 31: 151-159, 1998
30. Baliga MS, Meleth S, Katiyar SK: Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res 11:1918-1927, 2005
31. Sartippour MR, Heber D, Ma J, et al: Green tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 40:149-156, 2001
32. Xiao H, Hao X, Simi B, et al: Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis 29:113-119, 2008
33. Gao YT, McLaughlin JK, Blot WJ, et al: Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 86:855-858, 1994
34. Shanafelt T, Lee Y, Call T, et al: Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30: 707-712, 2006
35. Yang CS, Chen L, Lee MJ, et al: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7:351-354, 1998
36. Chow HH, Cai Y, Alberts DS, et al: Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10:53-58, 2001
37. Chow HH, Cai Y, Hakim IA, et al: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9:3312-3319, 2003
38. Pisters KM, Newman RA, Coldman B, et al: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19:1830-1838, 2001
39. Zhang X, Zhang H, Tighiouart M, et al: Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 123:1005-1014, 2008
40. Siddiqui IA, Malik A, Adhami VM, et al: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27:2055-2063, 2008
41. Kuttan R, Bhanumathy P, Nirmala K, et al: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29:197-202, 1985
42. Kuttan R, Sudheeran PC, Josph CD: Turmeric and curcumin as topical agents in cancer therapy. Tumori 73:29-31, 1987
43. NCI D: Clinical development plan: Curcumin. J Cell Biochem Suppl 26:72-85, 1996
44. Rao CV, Rivenson A, Simi B, et al: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259-266, 1995
45. Huang MT, Lou YR, Ma W, et al: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54:5841-5847, 1994
46. Kawamori T, Lubet R, Steele VE, et al: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/ progression stages of colon cancer. Cancer Res 59:597-601, 1999
47. Conney AH: Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: The Seventh DeWitt S. Goodman Lecture. Cancer Res 63:7005-7031, 2003
48. Li N, Chen X, Liao J, et al: Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23:1307-1313, 2002
49. Li M, Zhang Z, Hill DL, et al: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by downregulating the MDM2 oncogene through the PI3K/ mTOR/ETS2 pathway. Cancer Res 67:1988-1996, 2007
50. Kuttan G, Kumar KB, Guruvayoorappan C, et al: Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 595:173-184, 2007
51. Surh YJ, Chun KS: Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 595:149-172, 2007
52. Verma SP, Salamone E, Goldin B: Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 233: 692-696, 1997
53. Khafif A, Schantz SP, Chou TC, et al: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19:419-424, 1998
54. Sreepriya M, Bali G: Effects of administration of embelin and curcumin on lipid peroxidation, hepatic glutathione antioxidant defense and hematopoietic system during N-nitrosodiethylamine/ phenobarbital-induced hepatocarcinogenesis in Wistar rats. Mol Cell Biochem 284:49-55, 2006
55. Koo JY, Kim HJ, Jung KO, et al: Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 7:117-121, 2004
56. Kunnumakkara AB, Guha S, Krishnan S, et al: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861, 2007
57. Sen S, Sharma H, Singh N: Curcumin enhances vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331:1245-1252, 2005
58. Cruz-Correa M, Shoskes DA, Sanchez P, et al: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035-1038, 2006
59. Cheng AL, Hsu CH, Lin JK, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900, 2001
60. Sharma RA, McLelland HR, Hill KA, et al: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900, 2001
61. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220, 1997
62. Athar M, Back JH, Tang X, et al: Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274-283, 2007
63. Li ZG, Hong T, Shimada Y, et al: Suppression of N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23:1531-1536, 2002
64. Banerjee S, Bueso-Ramos C, Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthraceneinduced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62:4945-4954, 2002
65. Garvin S, Ollinger K, Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231:113-122, 2006
66. Gill C, Walsh SE, Morrissey C, et al: Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 67:1641-1653, 2007
67. Narayanan BA, Narayanan NK, Re GG, et al: Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 104:204-212, 2003
68. Aziz MH, Nihal M, Fu VX, et al: Resveratrolcaused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5:1335-1341, 2006
69. Ma X, Tian X, Huang X, et al: Resveratrolinduced mitochondrial dysfunction and apoptosis are associated with Ca2+ and mCICR-mediated MPT activation in HepG2 cells. Mol Cell Biochem 302:99-109, 2007
70. Sun ZJ, Pan CE, Liu HS, et al: Anti-hepatoma activity of resveratrol in vitro. World J Gastroenterol 8:79-81, 2002
71. Carbó N, Costelli P, Baccino FM, et al: Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 254:739-743, 1999
72. Ding XZ, Adrian TE: Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25:e71-e76, 2002
73. Kubota T, Uemura Y, Kobayashi M, et al: Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 23:4039-4046, 2003
74. Wu SL, Sun ZJ, Yu L, et al: Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 10:3048-3052, 2004
75. Revel A, Raanani H, Younglai E, et al: Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23:255-261, 2003
76. Boocock DJ, Faust GE, Patel KR, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252, 2007
77. Giovannucci E: Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 91:317-331, 1999
78. Seren S, Lieberman R, Bayraktar UD, et al: Lycopene in cancer prevention and treatment. Am J Ther 15:66-81, 2008
79. Franceschi S, Bidoli E, La Vecchia C, et al: Tomatoes and risk of digestive-tract cancers. Int J Cancer 59:181-184, 1994
80. Giovannucci E, Rimm EB, Liu Y, et al: A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94:391-398, 2002
81. García-Closas R, Castellsagué X, Bosch X, et al: The role of diet and nutrition in cervical carcinogenesis: A review of recent evidence. Int J Cancer 117:629-637, 2005
82. Schwarz S, Obermüller-Jevic UC, Hellmis E, et al: Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138: 49-53, 2008
83. Kim HS, Bowen P, Chen L, et al: Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer 47:40-47, 2003
84. Venkateswaran V, Fleshner NE, Sugar LM, et al: Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 64:5891-5896, 2004
85. Canene-Adams K, Lindshield BL, Wang S, et al: Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res 67:836-843, 2007
86. Kucuk O, Sarkar FH, Sakr W, et al: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10:861-868, 2001
87. Vaishampayan U, Hussain M, Banerjee M, et al: Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 59:1-7, 2007
88. Wang AH, Zhang LS: Effect of lycopene on the proliferation of MCF-7 and MDA-MB-231 cells. Sichuan Da Xue Xue Bao Yi Xue Ban 38:958-960: 976, 2007
89. Fornelli F, Leone A, Verdesca I, et al: The influence of lycopene on the proliferation of human breast cell line (MCF-7). Toxicol in Vitro 21:217-223, 2007
90. Sengupta A, Ghosh S, Das RK, et al: Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways. Eur J Cancer Prev 15:301-305, 2006
91. Levy J, Bosin E, Feldman B, et al: Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or betacarotene. Nutr Cancer 24:257-266, 1995
92. Kim DJ, Takasuka N, Kim JM, et al: Chemoprevention by lycopene of mouse lung neoplasia after combined initiation treatment with DEN, MNU and DMH. Cancer Lett 120:15-22, 1997
93. Kim DJ, Takasuka N, Nishino H, et al: Chemoprevention of lung cancer by lycopene. Biofactors 13:95-102, 2000
94. Michaud DS, Feskanich D, Rimm EB, et al: Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts. Am J Clin Nutr 72:990-997, 2000
95. Sahin K, Ozercan R, Onderci M, et al: Lycopene supplementation prevents the development of spontaneous smooth muscle tumors of the oviduct in Japanese quail. Nutr Cancer 50:181-189, 2004
96. Kim ND, Mehta R, Yu W, et al: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71:203-217, 2002
97. Toi M, Bando H, Ramachandran C, et al: Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 6:121-128, 2003
98. Zhang Y, Vareed SK, Nair MG: Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sci 76:1465-1472, 2005
99. Hora JJ, Maydew ER, Lansky EP, et al: Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J Med Food 6:157-161, 2003
100. Khan N, Hadi N, Afaq F, et al: Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28:163-173, 2007
101. Khan N, Afaq F, Kweon MH, et al: Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67:3475-3482, 2007
102. Malik A, Afaq F, Sarfaraz S, et al: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 102:14813-14818, 2005
103. Sartippour MR, Seeram NP, Rao JY, et al: Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 32:475-480, 2008
104. Pantuck AJ, Leppert JT, Zomorodian N, et al: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12: 4018-4026, 2006
105. Shimoi K, Saka N, Kaji K, et al: Metabolic fate of luteolin and its functional activity at focal site. Biofactors 12:181-186, 2000
106. Yang SF, Yang WE, Chang HR, et al: Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 87:401-406, 2008
107. Zhang Q, Zhao XH, Wang ZJ: Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol 46:2042-2053, 2008
108. Ju W, Wang X, Shi H, et al: A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factorkappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71:1381-1388, 2007
109. Lim do Y, Jeong Y, Tyner AL, et al: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 292:G66-G75, 2007
110. Selvendiran K, Koga H, Ueno T, et al: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res 66:4826-4834, 2006
111. Chiu FL, Lin JK: Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68:61-71, 2008
112. Wu B, Zhang Q, Shen W, et al: Antiproliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol Cell Biochem 313:125-132, 2008
113. Samy RP, Gopalakrishnakone P, Ignacimuthu S: Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chem Biol Interact 164:1-14, 2006
114. Manju V, Nalini N: Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct 25:189-194, 2007
115. Hebert JR, Hurley TG, Olendzki BC, et al: Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J Natl Cancer Inst 90:1637-1647, 1998
116. Adlercreutz H, Honjo H, Higashi A, et al: Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54:1093-1100, 1991
117. Ziegler RG, Hoover RN, Pike MC, et al: Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 85:1819-1827, 1993
118. Goodman MT, Wilkens LR, Hankin JH, et al: Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146:294-306, 1997
119. Hilakivi-Clarke L, Onojafe I, Raygada M, et al: Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 80: 1682-1688, 1999
120. Onozawa M, Kawamori T, Baba M, et al: Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 90:393-398, 1999
121. Lakshman M, Xu L, Ananthanarayanan V, et al: Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68:2024-2032, 2008
122. Wang Y, Raffoul JJ, Che M, et al: Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 166:73-80, 2006
123. Mohammad RM, Banerjee S, Li Y, et al: Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 106:1260-1268, 2006
124. Hussain M, Banerjee M, Sarkar FH, et al: Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47:111-117, 2003
125. Pendleton JM, Tan WW, Anai S, et al: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8:132, 2008
126. Jurenka JS: Therapeutic applications of pomegranate (Punica granatum L.): A review. Altern Med Rev 13:128-144, 2008
127. Heber D: Multitargeted therapy of cancer by ellagitannins. Cancer Lett 269:262-268, 2008
128. Chaturvedi PK, Bhui K, Shukla Y: Lupeol: Connotations for chemoprevention. Cancer Lett 263:1-13, 2008
129. Cichewicz RH, Kouzi SA: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24:90-114, 2004
130. Berquin IM, Edwards IJ, Chen YQ: Multitargeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269:363-377, 2008
131. Ye B, Aponte M, Dai Y, et al: Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence. Cancer Lett 251:43-52, 2007
132. DeFeudis FV, Papadopoulos V, Drieu K: Ginkgo biloba extracts and cancer: A research area in its infancy. Fundam Clin Pharmacol 17:405-417, 2003
133. Appella E, Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772, 2001
134. Bode AM, Dong Z: Post-translational modifi-cation of p53 in tumorigenesis. Nat Rev Cancer 4:793-805, 2004
135. Carr AM: Cell cycle: Piecing together the p53 puzzle. Science 287:1765-1766, 2000
136. Sherr CJ, Weber JD: The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99, 2000
137. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996
138. Agarwal MK, Amin AR, Agarwal ML: DNA replication licensing factor minichromosome maintenance deficient 5 rescues p53-mediated growth arrest. Cancer Res 67:116-121, 2007
139. Ho JS, Ma W, Mao DY, et al: p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25:7423-7431, 2005
140. Hastak K, Agarwal MK, Mukhtar H, et al: Ablation of either p21 or Bax prevent p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 19:789-791, 2005
141. Roy AM, Baliga MS, Katiyar SK: Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 4:81-90, 2005
142. Choudhuri T, Pal S, Agwarwal ML, et al: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 512:334-340, 2002
143. Tian B, Wang Z, Zhao Y, et al: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett 264:299-308, 2008
144. Shankar S, Srivastava RK: Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 30:905-918, 2007
145. Huang C, Ma WY, Goranson A, et al: Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20:237-242, 1999
146. Shankar S, Siddiqui I, Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxytrans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgeninsensitive prostate cancer cells. Mol Cell Biochem 304:273-285, 2007
147. Schmidt F, Knobbe CB, Frank B, et al: The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep 19:1061-1066, 2008
148. Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819, 1997
149. Yang A, Kaghad M, Wang Y, et al: P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominantnegative activities. Mol Cell 2:305-316, 1998
150. Amin AR, Thakur VS, Paul RK, et al: SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci U S A 104:5419-5424, 2007
151. Shammas MA, Neri P, Koley H, et al: Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: Biologic activity and therapeutic implications. Blood 108:2804-2810, 2006
152. Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203-208, 2004
153. Singh S, Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 270:24995-25000, 1995
154. Kasinski AL, Du Y, Thomas SL, et al: Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74:654-661, 2008
155. Manna SK, Mukhopadhyay A, Aggarwal BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164:6509-6519, 2000
156. Hastak K, Gupta S, Ahmad N, et al: Role of p53 and NF-kappaB in epigallocatechin-3-gallateinduced apoptosis of LNCaP cells. Oncogene 22: 4851-4859, 2003
157. Kim GY, Kim JH, Ahn SC, et al: Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. Immunology 113:203-211, 2004
158. Li Y, Kucuk O, Hussain M, et al: Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/ receptor activator of nuclear factor-κB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66:4816-4825, 2006
159. Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136, 2002
160. Kim HS, Kim MH, Jeong M, et al: EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 24:747-753, 2004
161. Kundu JK, Shin YK, Surh YJ: Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol 72:1506-1515, 2006
162. Dhandapani KM, Mahesh VB, Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102:522-538, 2007
163. Shimizu M, Deguchi A, Joe AK, et al: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5:69-78, 2005
164. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421, 1994
165. Grandis JR, Drenning SD, Chakraborty A, et al: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J Clin Invest 102:1385-1392, 1998
166. Leong H, Mathur PS, Greene GL: Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat; Epub ahead of print, 2008
167. Wung BS, Hsu MC, Wu CC, et al: Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: Effects on the inhibition of STAT3 phosphorylation. Life Sci 7 8:389-397, 2005
168. Bharti AC, Donato N, Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863-3871, 2003
169. Siddiqui IA, Shukla Y, Adhami VM, et al: Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res 25:2135-2142, 2008
170. Bhattacharyya S, Mandal D, Saha B, et al: Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282:15954-15964, 2007
171. Korutla L, Cheung JY, Mendelsohn J, et al: Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16:1741-1745, 1995
172. Patel BB, Sengupta R, Qazi S, et al: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122: 267-273, 2008
173. Masuda M, Suzui M, Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7:4220-4229, 2001
174. Adachi S, Nagao T, Ingolfsson HI, et al: The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 67:6493-6501, 2007
175. Shimizu M, Deguchi A, Hara Y, et al: EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun 334:947-953, 2005
176. Fang J, Zhou Q, Shi XL, et al: Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 28:713-723, 2007
177. Lee LT, Huang YT, Hwang JJ, et al: Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22:1615-1627, 2002
178. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148, 2004
179. Meeran SM, Mantena SK, Elmets CA: (-)-Epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interleukin-12-dependent DNA repair. Cancer Res 66:5512-5520, 2006
180. Mantena SK, Roy AM, Katiyar SK: Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol 81:1174-1179, 2005
181. Kang TH, Lee JH, Song CK, et al: Epigallocatechin-3-gallate enhances CD8+ T cellmediated antitumor immunity induced by DNA vaccination. Cancer Res 67:802-811, 2007
182. Guo TL, McCay JA, Zhang LX, et al: Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. J Nutr 131:3251-3258, 2001
183. Yang Y, Paik JH, Cho D, et al: Resveratrol induces the suppression of tumor-derived CD4+ CD25+ regulatory T cells. Int Immunopharmacol 8:542-547, 2008
184. Shankar S, Ganapathy S, Hingorani SR, et al: EGCG inhibits growth,
185. Bagli E, Stefaniotou M, Morbidelli L, et al: Luteolin inhibits vascular endothelial growth factorinduced angiogenesis: Inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res 64:7936-7946, 2004
186. Lin YG, Kunnumakkara AB, Nair A, et al: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factorkappaB pathway. Clin Cancer Res 13:3423-3430, 2007
187. Gururaj AE, Belakavadi M, Venkatesh DA, et al: Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 297: 934-942, 2002
188. Ahmad IU, Forman JD, Sarkar FH, et al: Reduction of adverse events by soy isoflavones in patients undergoing external beam radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 72:S318, 2008
189. Lippman SM, Heymach JV: The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13:4035-4041, 2007